港股上市的艾美疫苗(06660)在研产品,迎来关键进展。11月17日发布的公告显示,公司无血清迭代狂犬病疫苗已向国家药监局提交上市注册预申请。就在半个多月前,其13价结合肺炎疫苗也已向国家药监局提交药品上市注册,11月15日上市注册获受理。在利好频发背后,《财中社》注意到,艾美疫苗正在筹划A股上市。2023年10月8日晚间,公司决定启动首次公开发行A股上市的计划,聘请中信证券为上市前辅导机构。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.